Who are COVAX+IIV4; COVAX+PPV23's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Prevenar 13 + Pneumovax 23, MMR followed by YF, Healive+Havrix, Fluad and Prevenar13, immediate Cervarix, delayed MenVeo vaccine, Infanrix + Prevenar 13.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/covax-iiv4-covax-ppv23.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

COVAX+IIV4; COVAX+PPV23 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVAX+IIV4; COVAX+PPV23 (COVAX+IIV4; COVAX+PPV23) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine combination. Area: Immunology / Infectious Disease.

marketed vaccine combination Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

COVAX+IIV4; COVAX+PPV23 (COVAX+IIV4; COVAX+PPV23) — China National Biotec Group Company Limited. COVAX+IIV4 and COVAX+PPV23 are combination vaccines that provide immunization against COVID-19 (COVAX component) alongside seasonal influenza (IIV4) or pneumococcal disease (PPV23).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
COVAX+IIV4; COVAX+PPV23 TARGET	COVAX+IIV4; COVAX+PPV23	China National Biotec Group Company Limited	marketed	vaccine combination
Prevenar 13 + Pneumovax 23	Prevenar 13 + Pneumovax 23	Poitiers University Hospital	marketed	Pneumococcal vaccine combination
MMR followed by YF	MMR followed by YF	Alba Maria Ropero	marketed	Live attenuated viral vaccine combination
Healive+Havrix	Healive+Havrix	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine combination
Fluad and Prevenar13	Fluad and Prevenar13	Korea University Guro Hospital	marketed	vaccine combination
immediate Cervarix, delayed MenVeo vaccine	immediate Cervarix, delayed MenVeo vaccine	Massachusetts General Hospital	marketed	vaccine combination
Infanrix + Prevenar 13	Infanrix + Prevenar 13	University Hospital Tuebingen	phase 3	Vaccine combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (vaccine combination class)

China National Biotec Group Company Limited · 1 drug in this class
Korea University Guro Hospital · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). COVAX+IIV4; COVAX+PPV23 — Competitive Intelligence Brief. https://druglandscape.com/ci/covax-iiv4-covax-ppv23. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab